# US 2015/0104528 A1 · Treatment for depression and other mental conditions with synthetic isotope-modified lithium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104528 A1
- Document ID: US20150104528A1
- Status: Published application
- Kind: A1
- Application number: 14/512,292
- Filed: 2014-10-10
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Inventors: Matthew P. A. Fisher
- Web page: https://patentgrep.com/patent/US20150104528A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 8/19: containing inorganic ingredients
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above

## Claims

### Claim 1

A method for treating mental conditions, comprising administering a synthetic isotope-modified lithium-compound containing lithium-6 isotopes in an amount of at least 95% of a total number of lithium atoms in the compound, at dosages of about 100 mg/day to 1500 mg/day, whereby a symptom of the mental condition is alleviated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mental condition is selected from the group consisting of depression, attention deficit disorder, dementia, reduced alertness, amnesia, and poor memory recall.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mental condition is depression.

### Claim 4 (depends on 3)

The method of claim 3, wherein the dosages range from 100 mg/day to less than 300 mg/day.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound is selected from the group consisting of lithium carbonate, lithium citrate, lithium-chloride.

### Claim 6 (depends on 5)

The method of claim 5, wherein the compound is lithium carbonate.

### Claim 7

A method of treating mental conditions comprising administering a synthetic isotope-modified lithium-compound containing lithium-7 isotopes in an amount of at least 95% of a total number of lithium atoms in the compound, at dosages of 200 mg/day to 1200 mg/day, whereby a symptom of the mental condition is alleviated.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mental condition is selected from the group consisting of mania and bipolar disorder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mental condition is mania.

### Claim 10 (depends on 9)

The method of claim 9, wherein the lithium carbonate is administered at dosages of 200 mg/day to less than 300 mg/day.

### Claim 11 (depends on 10)

The method of claim 10, wherein the compound is selected from the group consisting of lithium carbonate, lithium citrate, lithium orotate, and lithium-chloride.

### Claim 12 (depends on 11)

The method of claim 11, wherein the compound is lithium carbonate.

### Claim 13

A method of treating mental conditions by administering a synthetic isotope-modified lithium-compound containing lithium-6 isotopes in an amount ranging from 10% to 95% of a total number of lithium atoms in the compound, wherein the compound is administered at dosages ranging from 100 mg/day to 1500 mg/day, whereby a symptom of the mental condition is alleviated.

### Claim 14 (depends on 13)

The method of claim 13, wherein the lithium-6 isotopes are present in an amount between 25% and 85% of the total number of lithium atoms in the compound.

### Claim 15 (depends on 13)

The method of claim 13, wherein the lithium-6 isotopes are present in an amount between 35% and 75% of the total number of lithium atoms in the compound.

### Claim 16 (depends on 13)

The method of claim 13, wherein the lithium-6 isotopes are present in an amount between 45% and 65% of the total number of lithium atoms in the compound.

### Claim 17 (depends on 13)

The method of claim 13, wherein the dosages range from 100 mg/day to less than 300 mg/day.

### Claim 18 (depends on 13)

The method of claim 13, wherein the mental condition is selected from the group consisting of depression, attention deficit disorder, dementia, reduced alertness, amnesia, poor memory recall, mania, and bipolar disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the mental condition is depression.
